NCT03182699View on ClinicalTrials.gov

Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

December 20, 2019

Study Completion Date

December 20, 2019

Conditions
Secondary HyperparathyroidismChronic Kidney Disease Requiring Chronic DialysisLeft Ventricular Hypertrophy
Interventions
DIAGNOSTIC_TEST

cardiac MRI

non contrast heart MRI at baseline and after 1 year of therapy

DIAGNOSTIC_TEST

echocardiography with strain

echocardiography at baseline and after 1 year of therapy

DIAGNOSTIC_TEST

Laboratory tests

drawing blood from dialysis machine

DIAGNOSTIC_TEST

Body composition monitoring

Measurement with BCM (Fresenius) machine

DIAGNOSTIC_TEST

lung ultrasound

ultrasound

Trial Locations (2)

1090

Medical University of Vienna, Vienna

1220

Wiener Dialysezentrum, Vienna

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Rainer Oberbauer

OTHER